|
 The company's shares rose about 3 percent to $1.97
in premarket trading on Thursday.
Cell Therapeutics said it received the notification from the
regulator on December 26.
The FDA placed the hold after a patient treated with a combination
of the drug, tosedostat, and a chemotherapy drug died of a heart
muscle infection.
Under the hold, the company could not enroll new patients in any
trials of tosedostat.
The regulator asked for more information on all heart-related events
in patients treated with the drug.
[to top of second column] |
Tosedostat is being tested in mid-stage trials in the United States
and European Union on elderly patients with two forms of blood
cancer — acute myeloid leukemia and myelodysplastic syndrome.
(Reporting by Vrinda Manocha in
Bangalore; editing by Kirti Pandey)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
